Problems reported with wrinkle fillers in U.S.

By Lisa Richwine

WASHINGTON (Reuters) - U.S. regulators have received reports of serious and unexpected problems in people treated with wrinkle-fighting injections known as dermal fillers, Food and Drug Administration staff said in a report released on Friday.

The problems included facial palsy, disfigurement and “rare but life-threatening events such as severe allergic reactions and anaphylactic shock,” the FDA staff said.

The agency said it received a total of 930 reports of health problems over the past six years. Many included known complications such as minor swelling. The FDA did not identify which products had reports of more serious problems.

The FDA staff said the reports had several limitations such as failing to say when the problems started.

Dermal fillers include Allergan Inc’s Juvederm, Restylane and Perlane from Medicis, and Bioform Medical’s Radiesse.

The FDA will ask a panel of outside experts that meets on Tuesday if labels for the products should be changed, agency staff said.

Medicis Chief Executive Jonah Shacknai, in an interview with Reuters, said, “We do not see any adverse events that are unexpected or unnoted on our product label.

“We haven’t seen anything that is life-threatening,” he added.

Allergan spokeswoman Caroline Van Hove said no serious problems were seen in clinical trials of Juvederm, and the most common complaint since its approval was swelling in 0.4 percent of patients.

“Juvederm has a highly favorable safety profile based on long-term use and volume,” she said.

An official at Bioform Medical could not immediately be reached for comment.

The report was posted on the FDA website here

(Editing by Leslie Gevirtz)


Related Posts:

By Ransdell Pierson NEW YORK (Reuters) - U.S. regulators on Tuesday said their review of clinical trials does not suggest Merck & Co’s Singulair asthma drug or similar medicines cause suicide or suicidal thought, although the data were inadequate to draw a firm conclusion. However, the U.S. Food and Drug Administration said it was continuing to review

Full Post: FDA says Singulair data do not suggest suicide link

ROCKVILLE, Maryland (Reuters) - An Allergan Inc glaucoma drug is safe and effective enough for U.S. regulators to approve cosmetic use to lengthen and thicken eyelashes, a U.S. advisory panel unanimously ruled on Friday. The drug is known generically as bimatoprost and is sold for glaucoma under the name Lumigan. Allergan estimates the eyelash use could

Full Post: Allergan eyelash drug wins U.S. panel backing

VANCOUVER, British Columbia (Reuters) - Canadian health officials urged parents on Thursday not to give over-the-counter cold medicines to children under the age of six, citing concern over misuse and overdoses. The federal health agency, Health Canada, which had earlier this year recommended the medicines not be given to children less than two years old, said

Full Post: Canada sets new limits on cold medicine for children

NEW YORK (Reuters) - New data do not signal any heart risks with Takeda Pharmaceutical Co Ltd’s experimental drug to treat acid build-up in patients with gout, a top U.S. Food and Drug Administration official said in a document released on Thursday. Takeda is seeking U.S. approval to sell its drug febuxostat for chronic gout patients

Full Post: No heart risk seen with Takeda gout drug: FDA

BOSTON (Reuters) - Allergan Inc, maker of Botox, said on Friday that the U.S. Food and Drug Administration has approved its eyelash-thickening drug Latisse. Latisse is designed to treat a condition known as hypotrichosis of the eyelashes, in which a person has does not have enough eyelashes. The active ingredient in Latisse is bimatroprost, the same ingredient

Full Post: FDA approves Allergan’s drug for longer eyelashes

Site Navigation

Most Read